Research programme: pain therapeutics - TransMolecular

Drug Profile

Research programme: pain therapeutics - TransMolecular

Latest Information Update: 27 Nov 2007

Price : $50

At a glance

  • Originator TransMolecular
  • Class
  • Mechanism of Action Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 11 Jul 2003 Early research in Pain in USA (unspecified route)
  • 11 Jul 2003 Transmolecular is seeking partners to develop new chemical entries for the treatment of pain in the US (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top